Global Endometriosis Pain - Pipeline Insight, 2022

This “Endometriosis Pain - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Endometriosis Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Endometriosis Pain Understanding

Endometriosis Pain: Overview

Endometriosis is a chronic and debilitating condition affecting ∼10% of women. Endometriosis is characterized by infertility and chronic pelvic pain, yet treatment options remain limited. In many respects this is related to an underlying lack of knowledge of the etiology and mechanisms contributing to endometriosis-induced pain. Whilst many studies focus on retrograde menstruation, and the formation and development of lesions in the pathogenesis of endometriosis, the mechanisms underlying the associated pain remain poorly described. Here we review the recent clinical and experimental evidence of the mechanisms contributing to chronic pain in endometriosis. This includes the roles of inflammation, neurogenic inflammation, neuroangiogenesis, peripheral sensitization and central sensitization. Endometriosis is diagnosed surgically by the presence of endometrial lesions outside of the uterus. However, surgical intervention and diagnosis are usually preceded by bouts of chronic abdominal pain and/or CPP, leading patients to present to their consulting physician. More than 60% of women diagnosed with endometriosis report CPP, with endometriosis patients 13 times more likely to experience abdominal pain than healthy subjects.

"Endometriosis Pain - Pipeline Insight, 2022" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometriosis Pain pipeline landscape is provided which includes the disease overview and Endometriosis Pain treatment guidelines. The assessment part of the report embraces, in depth Endometriosis Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometriosis Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Endometriosis Pain.
• In the coming years, the Endometriosis Pain market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Endometriosis Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Endometriosis Pain treatment market. Several potential therapies for Endometriosis Pain are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Endometriosis Pain market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Endometriosis Pain) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Endometriosis Pain Emerging Drugs Chapters

This segment of the Endometriosis Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endometriosis Pain Emerging Drugs

Quinagolide: Ferring

PharmaceuticalsQuinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis 1. Newer dopamine receptor agonists such as quinagolide and Cabergoline are shown to effectively inhibit prolactin secretion with improved efficacy over Bromocriptine. These drugs are effective in patients who are intolerant or resistant to Bromocriptine. Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer. It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. The drug is currently in Phase II stage of clinical trial evaluation to treat Endometriosis-related Pain.

Linzagolix: ObsEva

Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments. Unlike marketed GnRH agonists, Linzagolix has the potential to be administered orally once a day, with symptoms relieved within days, while potentially mitigating the initial worsening of symptoms often associated with GnRH agonist treatments. Linzagolix has the potential to dose-dependently lower estradiol levels hence maintaining such levels within an optimal range to mitigate patient bone mineral density loss. Linzagolix has the potential to allow patients to receive the relief needed to live normal lives again and enhance their quality of life with fewer side effects and complications requiring doctor's visits or surgery.

Endometriosis Pain: Therapeutic Assessment

This segment of the report provides insights about the different Endometriosis Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endometriosis Pain

There are approx. 5+ key companies which are developing the therapies for Endometriosis Pain. The companies which have their Endometriosis Pain drug candidates in the most advanced stage, i.e. phase III include, ObsEva.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Endometriosis Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endometriosis Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endometriosis Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometriosis Pain drugs.

Endometriosis Pain Report Insights

• Endometriosis Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Endometriosis Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Endometriosis Pain drugs?
• How many Endometriosis Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometriosis Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endometriosis Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Endometriosis Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ferring Pharmaceuticals
• ObsEva SA
• Myovant Sciences
• Hope Medicine (Nanjing) Co., Ltd
• TiumBio Co., Ltd.
• Mitsubishi Tanabe Pharma

Key Products

• Quinagolide
• Linzagolix
• Estradiol/norethindrone acetate
• HMI-115
• TU2670
• MT-2990

This product will be delivered within 2 business days.